JP2022519772A5 - - Google Patents
Info
- Publication number
- JP2022519772A5 JP2022519772A5 JP2021547531A JP2021547531A JP2022519772A5 JP 2022519772 A5 JP2022519772 A5 JP 2022519772A5 JP 2021547531 A JP2021547531 A JP 2021547531A JP 2021547531 A JP2021547531 A JP 2021547531A JP 2022519772 A5 JP2022519772 A5 JP 2022519772A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- independently selected
- heterocycloalkyl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806265P | 2019-02-15 | 2019-02-15 | |
| US62/806,265 | 2019-02-15 | ||
| PCT/US2020/018271 WO2020168178A1 (en) | 2019-02-15 | 2020-02-14 | Cyclin-dependent kinase 2 biomarkers and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519772A JP2022519772A (ja) | 2022-03-24 |
| JP2022519772A5 true JP2022519772A5 (enExample) | 2023-02-21 |
Family
ID=69811930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547531A Pending JP2022519772A (ja) | 2019-02-15 | 2020-02-14 | サイクリン依存性キナーゼ２バイオマーカー及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200316064A1 (enExample) |
| EP (1) | EP3923949A1 (enExample) |
| JP (1) | JP2022519772A (enExample) |
| KR (1) | KR20210139269A (enExample) |
| CN (1) | CN114040764A (enExample) |
| AU (2) | AU2020221293A1 (enExample) |
| CA (1) | CA3130210A1 (enExample) |
| EA (1) | EA202192260A1 (enExample) |
| IL (1) | IL285574A (enExample) |
| MA (1) | MA54947A (enExample) |
| MX (1) | MX2021009682A (enExample) |
| PH (1) | PH12021551976A1 (enExample) |
| SG (1) | SG11202108702XA (enExample) |
| TW (1) | TW202045181A (enExample) |
| WO (1) | WO2020168178A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| JP7667147B2 (ja) * | 2019-10-17 | 2025-04-22 | シーセン ファーマシューティカル カンパニー リミテッド | Ｃｄｋ２／４／６三重阻害剤としてのアミノピリミジン化合物 |
| JP2021167301A (ja) * | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| UY40638A (es) | 2023-02-17 | 2024-08-30 | Novartis Ag | Inhibidores de quinasa dependientes de ciclina (cdk2) |
| CN118619950A (zh) * | 2023-03-10 | 2024-09-10 | 浙江同源康医药股份有限公司 | 一类三环类化合物及其制备和应用 |
| WO2024254245A1 (en) | 2023-06-09 | 2024-12-12 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| CN116898857A (zh) * | 2023-06-19 | 2023-10-20 | 中国人民解放军空军军医大学 | RGB-286638 free base在制备治疗食管鳞癌的药物中的应用 |
| WO2025175258A1 (en) * | 2024-02-17 | 2025-08-21 | Padarn Therapeutics, Inc. | Inhibitors of cdk2 |
| WO2025188779A1 (en) * | 2024-03-04 | 2025-09-12 | Blueprint Medicines Corporation | Cdk2 inhibitors for treatment of cancer |
| WO2026038121A1 (en) * | 2024-08-12 | 2026-02-19 | Novartis Ag | Uses of a cdk2 inhibitor in the treatment of cancer |
| WO2026038120A1 (en) * | 2024-08-12 | 2026-02-19 | Novartis Ag | Synthesis and crystalline forms of a cdk2 inhibitor |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| US6812341B1 (en) | 2001-05-11 | 2004-11-02 | Ambion, Inc. | High efficiency mRNA isolation methods and compositions |
| BR0212760A (pt) | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| DE60213842T2 (de) | 2001-10-30 | 2007-09-06 | Novartis Ag | Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7252976B2 (en) | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EA201001030A1 (ru) | 2007-12-19 | 2011-02-28 | Амген Инк. | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| MX338327B (es) | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| EP2937349B1 (en) | 2011-03-23 | 2016-12-28 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| WO2015095840A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
| TWI712601B (zh) * | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20190345558A1 (en) * | 2016-05-18 | 2019-11-14 | Université Libre de Bruxelles | Method for determining sensitivity to a cdk4/6 inhibitor |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| PT3497103T (pt) * | 2016-08-15 | 2021-06-17 | Pfizer | Inibidores de piridopirimidinona cdk2/4/6 |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| SMT202500157T1 (it) | 2018-03-30 | 2025-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| HUE061503T2 (hu) | 2018-05-11 | 2023-07-28 | Incyte Corp | Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok |
| US12448448B2 (en) | 2018-06-20 | 2025-10-21 | Incyte Corporation | Anti-PD-1 antibodies and uses thereof |
| WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) * | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) * | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
-
2020
- 2020-02-14 PH PH1/2021/551976A patent/PH12021551976A1/en unknown
- 2020-02-14 MA MA054947A patent/MA54947A/fr unknown
- 2020-02-14 TW TW109104735A patent/TW202045181A/zh unknown
- 2020-02-14 EA EA202192260A patent/EA202192260A1/ru unknown
- 2020-02-14 WO PCT/US2020/018271 patent/WO2020168178A1/en not_active Ceased
- 2020-02-14 CA CA3130210A patent/CA3130210A1/en active Pending
- 2020-02-14 CN CN202080027758.8A patent/CN114040764A/zh active Pending
- 2020-02-14 US US16/791,561 patent/US20200316064A1/en active Pending
- 2020-02-14 MX MX2021009682A patent/MX2021009682A/es unknown
- 2020-02-14 KR KR1020217029440A patent/KR20210139269A/ko not_active Ceased
- 2020-02-14 SG SG11202108702XA patent/SG11202108702XA/en unknown
- 2020-02-14 JP JP2021547531A patent/JP2022519772A/ja active Pending
- 2020-02-14 EP EP20711427.3A patent/EP3923949A1/en active Pending
- 2020-02-14 AU AU2020221293A patent/AU2020221293A1/en not_active Abandoned
-
2021
- 2021-08-12 IL IL285574A patent/IL285574A/en unknown
-
2025
- 2025-11-03 AU AU2025260019A patent/AU2025260019A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519772A5 (enExample) | ||
| JP2022551668A5 (enExample) | ||
| Ihle et al. | Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | |
| US20240082251A1 (en) | Dosing regimen of kras g12c inhibitor | |
| Cloughesy et al. | Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | |
| Fan et al. | Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance | |
| Hong et al. | A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma | |
| US12297210B2 (en) | Naphthyridine compounds and uses thereof | |
| US9504729B2 (en) | Antiangiogenic small molecules and methods of use | |
| Guillard et al. | Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma | |
| US20160279135A1 (en) | Therapies for treating myeloproliferative disorders | |
| JP2023519931A5 (enExample) | ||
| Hollebecque et al. | A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours | |
| CN105611940A (zh) | 诊断方法和用于治疗成胶质细胞瘤的组合物 | |
| Xu et al. | Stabilization of MDA-7/IL-24 for colon cancer therapy | |
| Song et al. | Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells | |
| US11696924B2 (en) | Combination therapy using PDK1 and PI3K inhibitors | |
| Zhu et al. | Discovery of novel fourth-generation EGFR inhibitors to overcome C797S-mediated resistance | |
| US11994511B2 (en) | Biomarkers indicative of prostate cancer and treatment thereof | |
| WO2020202232A1 (en) | Compounds having anti-cdk4/6 and anti-cdk9 enzymatic activities for inhibiting cancer proliferation and related screening method for their detection | |
| WO2008106408A1 (en) | Treatment of cancer with bio and chemotherapy | |
| US20050171182A1 (en) | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases | |
| Bossi | MKK3 as oncotarget | |
| WO2024039883A2 (en) | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms | |
| US10213449B2 (en) | Compositions and methods for treating medulloblastoma |